A Potential New BNCT Agent

Galactose Containing 1-Amino-3[2-(1,7-Dicarba-closo-Dodecaboran-1-YL)Ethyl]-Cyclobutanecarboxylic Acid
  • G. W. Kabalka
  • G. Li
  • R. R. Srivastava

Abstract

Boron neutron capture therapy (BNCT) is a binary approach to cancer therapy.1 In this protocol, boron-10 is delivered to the tumor tissue, and upon irradiation with thermal neutrons, cytotoxic α-particles and high energy lithium-7 ions are produced. The linear energy transfer (LET) of these heavy charged particles (which is on the order of one cell diameter) makes them lethal to the boron-containing cells. The success of this protocol is dependent upon the selective delivery of a sufficient quantity of boron-10 to the tumor tissues (10–30μg boron-10/g of tumor with tumor to normal tissue ratio of 3:1). While various carrier molecules are under investigation as potential boron-delivery agents, the only drug currently in clinical trials in the United States is a boron-containing amino acid,2 4-dihydroxyborylphenylalanine (BPA).

Keywords

Ethyl Cage Boron Ketone Cyanide 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    A.H. Soloway, W.Tjarks, B.A. Barnum, F.-G. Ronj, R.F. Barth, I.M. Codogni, and J.G. Wilson, The Chemistry of Neutron Capture Therapy, Chem. Rev., 98:1515, 1998.PubMedCrossRefGoogle Scholar
  2. 2.
    J.A. Coderre, E.H. Elowitz, M. Chadha, R. Bergtland, J. Capala, D.D. Joel, H.B. Liu, D.N. Slatkin, and A.D. Chanana, Boron Neutron Capture Therapy for Glioblastoma Multiforme Using p-Boronopheny- lalanine and Epithermal Neutrons: Trial Design and Early Clinical Results, J. Neurooncol. 33:141, 1997.PubMedCrossRefGoogle Scholar
  3. 3.
    K.F. Hubner, G.T. Smith, J.A. Thie, and E. Buonocore, Dynamic Positron Emission Tomography (PET) of Brain Tumors Using l-Aminocyclobutane[C-ll]carboxylic Acid (C-ll ACBC) and A 2-Component Model, J. Nucl. Med., 33:922, 1992.Google Scholar
  4. 4.
    R.N. Grimes, “Carborane,” Academic Press, New York and London, 1970.Google Scholar
  5. 5.
    R.R. Srivastava, R.R. Singhaus, and G.W. Kabalka, Synthesis of l-Amino-3[2-(l,7-dicarba-closo-dode-caboran(12)-l-yl)ethyl]cyclobutanecarboxylic Acid: A Potential BNCT Agent, J. Org. Chem., 62:4477, 1997.Google Scholar
  6. 6.
    R.R. Srivastava, and G.W. Kabalka, Synthesis of l-Amino-3[2-(7-(2-hydroxyethyl)l,7-dicarba-closo-dodecaboran(12)-l-yl)ethyl]-cyclobutanecarboxylic Acid and Its nido-Analogue: Potential BNCT Agents, J. Org. Chem., 62:8730, 1997.CrossRefGoogle Scholar
  7. 7.
    D. Djerass, M. Shamma, and T.Y. Kar, Studies in Organic Sulfur Compounds. X. The Scope of the Raney Nickel Desulfurization of Cyclic Hemithioketals (1,3-Oxathiolanes and 1,3-Oxathianes), J. Am. Chem. Soc., 80:4723, 1958.CrossRefGoogle Scholar
  8. 8.
    R.W. Binkley, M.G. Ambrose, and D.G. Hehemann, Synthesis of Deoxyhalogeno Sugars. Displacement of the (Trifluoromethanesulfonyl)oxy (Triflyl) Group by Halide Ion, J. Org. Chem., 45:4387, 1980.CrossRefGoogle Scholar
  9. 9.
    H.R. Henze, and R.J. Speer, Identification of Carbonyl Compounds through Conversion into Hydantoins, J. Org. Chem., 2:1316, 1942.Google Scholar
  10. 10.
    Analytical data of galactose-containing meta-carboranyl ACBC 3: 1H NMR (CD3OD) δ 4.35 (d, J = 5.80Hz, 1H), 4.00-3.40 (m, 4H), 2.66 (m, 2H), 2.42 (m, 3H), 2.20-1.75 (m, 4H), 1.61 (m, 2H). 13C NMR (CD3OD) δ 176.64, 98.18 (94.06), 77.35, 75.30, 74.96 (75.11), 74.84 (71.07), 73.62 (70.25), 72.97 (70.17), 55.91 (58.20), 40.09, 37.66 (38.47), 36.02(36.69), 35.33(35.80), 29.07 (28.85). Anal. Calcd. for C15H34BC1N07: C, 37.22; H, 7.08; N, 2.89. Found: C, 36.97; H, 7.05; N, 2.67.Google Scholar

Copyright information

© Springer Science+Business Media New York 2001

Authors and Affiliations

  • G. W. Kabalka
    • 1
  • G. Li
    • 1
  • R. R. Srivastava
    • 1
  1. 1.Department of Chemistry and RadiologyThe University of TennesseeKnoxvilleUSA

Personalised recommendations